Monthly Archives: January 2010

I’m giving a talk at Pittcon on biotechnology training this spring. As many readers know, I have been very active in biotechnology education through my books and the classes I teach. So, I’ve got a strong sense of the supply-side of biotechnology education and training, and the academic side of biotechnology education, but would like some more perspective on the industry side of biotechnology education and training.

So, I’d like to post an open question:

How do you train your new biotechnology employees?

I want to learn more about the training systems used to bring new hires, with either scientific or business backgrounds, up to speed on the business of biotechnology. What are the methods and tools you use? You may post your response in the comments below, or if you’d rather be off the record, feel free to contact me directly.

I’m honored to have been selected as one of the judges of the 2010 Biotech Humanitarian award. More details are available in a press release and blog post about the award.  The Biotechnology Industry Association created the Award to recognize an everyday hero who has helped to heal, fuel and feed the planet through their work in the broad biotech arena.

BIO is accepting nominations for the 2010 Award via through January 31, 2010.

The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 16, Issue 1


Time for a new business model? PDF
Yali Friedman


Why data exclusivity is the new patent protection PDF
Peter J Pitts
Follow-on biologic drug competition – No need for new marketing exclusivities PDF
Michael S Wroblewski, Elizabeth A Jex


Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb PDF
Nigel Borshell, Adrian Dawkes
Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms PDF
Mark J Ahn, Michael Meeks, Sally Davenport, Rebecca Bednarek
Intellectual property landscape and patenting opportunity in biofuels PDF
Ramasamy Mannan
Challenges and opportunities in the licensing of renewable technologies PDF
Meredith Lloyd-Evans, Mike Gilbert, Ilian P Iliev
Ethiopia: Biotechnology for development PDF
Desta Berhe Sbhatu
Innovation and commercialisation in the stem cell industries in Australia: State strategies and other opportunities to build a competitive position in the global stem cell economy PDF
Olivia Harvey

Legal and Regulatory Updates

Using IP audits to optimize IP assets PDF
James G Cullem

Book Reviews

Book Review: Health-care investing: Profiting from the new world of pharma, biotech and health-care services PDF
Frank LaSaracina
Book Review: Aging, Biotechnology, and the Future PDF
Harley King

Drug Patent Expirations in January 2010

*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
XOPENEX Sepracor levalbuterol hydrochloride 6,083,993 Jan 5, 2010
XOPENEX HFA Sepracor levalbuterol tartrate 5,844,002 Jan 5, 2010
XOPENEX Sepracor levalbuterol hydrochloride 5,844,002 Jan 5, 2010
XOPENEX HFA Sepracor levalbuterol tartrate 5,760,090 Jan 5, 2010
XOPENEX HFA Sepracor levalbuterol tartrate 6,083,993 Jan 5, 2010
XOPENEX Sepracor levalbuterol hydrochloride 5,760,090 Jan 5, 2010
MONOPRIL Bristol Myers Squibb fosinopril sodium 5,006,344*PED Jan 10, 2010
MONOPRIL-HCT Bristol Myers Squibb fosinopril sodium; hydrochlorothiazide 5,006,344*PED Jan 10, 2010
CLARINEX Schering desloratadine 5,178,878 Jan 12, 2010
REMERON SOLTAB Organon Usa Inc mirtazapine 5,178,878 Jan 12, 2010
ORAPRED ODT Sciele Pharma Inc prednisolone sodium phosphate 5,178,878 Jan 12, 2010
FAZACLO ODT Azur Pharma Intl clozapine 5,178,878 Jan 12, 2010
ALLEGRA Sanofi Aventis Us fexofenadine hydrochloride 5,178,878 Jan 12, 2010
REFLUDAN Bayer Hlthcare lepirudin recombinant 5,180,668 Jan 19, 2010
ELMIRON Ortho Mcneil Janssen pentosan polysulfate sodium 5,180,715 Jan 19, 2010
VFEND Pfizer voriconazole 5,376,645 Jan 23, 2010
GEODON Pfizer ziprasidone mesylate 5,376,645 Jan 23, 2010
NEXTERONE Prism Pharms amiodarone hydrochloride 5,134,127 Jan 23, 2010
VFEND Pfizer voriconazole 5,134,127 Jan 23, 2010
GEODON Pfizer ziprasidone mesylate 5,134,127 Jan 23, 2010

Courtesy of

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.